An efficacy readout in a small Phase IIa trial of Aclaris’ oral therapy for rheumatoid arthritis has more than tripled the company’s market cap, representing its first major value-creating event since it restructured in 2H19...

Endeavor launched Thursday with $62 million from a series A financing round led by Omega Funds and Longitude Capital to treat pulmonary diseases, starting with a hedgehog pathway inhibitor in-licensed from Eli Lilly. John Hood,...

Covaxx licenses COVID vaccine to Aurobindo Aurobindo Pharma Ltd. (NSE:AUROPHARMA; BSE:524804) gained exclusive rights from the Covaxx unit of United Biomedical Inc. to develop and market UB-612 in India...

While the pandemic has put much of normal life on hold, the biotech industry has continued to hum along, funding and advancing R&D while simultaneously ushering the world into the post-COVID era one...

Four months after Jyseleca’s surprise setback at FDA, Gilead and Galapagos are abandoning U.S. development of the therapy that was once the centerpiece of a $5 billion deal between the companies.  ...

In its December opinions, EMA’s CHMP recommended a restriction for Gilead’s Veklury, specifying that COVID-19 patients should be on low- or high-flow oxygen or other non-invasive ventilation at the start of treatment.  The committee also...

Evelo’s Phase Ib readout in atopic dermatitis strengthens the case for its platform of oral microbiome-derived, gut-restricted therapies to modulate systemic immune activity. Evelo Biosciences Inc. (NASDAQ:EVLO)...

Kinaset is launching with a $40 million series A led by  5AM Ventures and Atlas Venture with participation from Gimv to develop an inhaled immunomodulator that will compete with biologics in severe...